Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.
Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R. Van den Berghe G, et al. Among authors: bowers cy. Clin Endocrinol (Oxf). 2002 May;56(5):655-69. doi: 10.1046/j.1365-2265.2002.01255.x. Clin Endocrinol (Oxf). 2002. PMID: 12030918 Clinical Trial.
Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C, Lauwers P, Bouillon R. Van den Berghe G, et al. Among authors: bowers cy. Clin Endocrinol (Oxf). 1996 Sep;45(3):341-51. doi: 10.1046/j.1365-2265.1996.00805.x. Clin Endocrinol (Oxf). 1996. PMID: 8949573 Clinical Trial.
The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers CY. Van den Berghe G, et al. Among authors: bowers cy. J Clin Endocrinol Metab. 1997 Feb;82(2):590-9. doi: 10.1210/jcem.82.2.3736. J Clin Endocrinol Metab. 1997. PMID: 9024260 Clinical Trial.
Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R, Bowers CY. Van den Berghe G, et al. Among authors: bowers cy. Clin Endocrinol (Oxf). 1997 Nov;47(5):599-612. doi: 10.1046/j.1365-2265.1997.3371118.x. Clin Endocrinol (Oxf). 1997. PMID: 9425400 Clinical Trial.
Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest C, Van der Vorst E, Lauwers P, Bouillon R, Bowers CY. Van den Berghe G, et al. Among authors: bowers cy. J Clin Endocrinol Metab. 1998 Feb;83(2):309-19. doi: 10.1210/jcem.83.2.4575. J Clin Endocrinol Metab. 1998. PMID: 9467533 Clinical Trial.
Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.
Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R. Van den Berghe G, et al. Among authors: bowers cy. J Clin Endocrinol Metab. 1999 Apr;84(4):1311-23. doi: 10.1210/jcem.84.4.5636. J Clin Endocrinol Metab. 1999. PMID: 10199772 Clinical Trial.
318 results